These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 24731783)

  • 1. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.
    Kaufman M; Pardo G; Rossman H; Sweetser MT; Forrestal F; Duda P
    J Neurol Sci; 2014 Jun; 341(1-2):22-7. PubMed ID: 24731783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immune response to influenza vaccine in natalizumab-treated MS patients.
    Vågberg M; Kumlin U; Svenningsson A
    Neurol Res; 2012 Sep; 34(7):730-3. PubMed ID: 22709910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
    Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
    Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
    Oliver B; Fernández O; Orpez T; Alvarenga MP; Pinto-Medel MJ; Guerrero M; León A; López-Madrona JC; Maldonado-Sánchez R; García-León JA; Luque G; Fernández V; Leyva L
    Mult Scler; 2011 Mar; 17(3):368-71. PubMed ID: 21177326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Natalizumab as induction therapy in multiple sclerosis].
    Corlobé A; Charif M; Mania A; Outteryck O; de Sèze J; Labauge P
    Rev Neurol (Paris); 2014 Jan; 170(1):2-5. PubMed ID: 24125463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
    Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
    Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.
    Sørensen PS; Jensen PE; Haghikia A; Lundkvist M; Vedeler C; Sellebjerg F; Koch-Henriksen N; Fogdell-Hahn A; Myhr KM; Hillert J; Gold R
    Mult Scler; 2011 Sep; 17(9):1074-8. PubMed ID: 21511692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
    Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid.
    Mellergård J; Edström M; Vrethem M; Ernerudh J; Dahle C
    Mult Scler; 2010 Feb; 16(2):208-17. PubMed ID: 20007431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.
    Fernández-Megía MJ; Casanova B; Magraner MJ; Font-Noguera I; Poveda-Andrés JL
    Farm Hosp; 2011; 35(2):75-9. PubMed ID: 20685144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress.
    Bahamonde C; Conde C; Agüera E; Lillo R; Luque E; Gascón F; Feijóo M; Cruz AH; Sánchez-López F; Túnez I
    Eur J Pharmacol; 2014 May; 730():26-30. PubMed ID: 24582759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M; Schiavetti I; De Mercanti SF; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Ghezzi A; Bianchi A; Salemi G; Realmuto S; Sola P; Vitetta F; Cavalla P; Paolicelli D; Trojano M; Sormani MP; Durelli L
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
    Bar-Or A; Calkwood JC; Chognot C; Evershed J; Fox EJ; Herman A; Manfrini M; McNamara J; Robertson DS; Stokmaier D; Wendt JK; Winthrop KL; Traboulsee A
    Neurology; 2020 Oct; 95(14):e1999-e2008. PubMed ID: 32727835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.